S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NASDAQ:MESO

Mesoblast Competitors

$9.17
-0.01 (-0.11 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.75
Now: $9.17
$9.30
50-Day Range
$8.94
MA: $9.73
$10.95
52-Week Range
$3.12
Now: $9.17
$21.28
Volume218,973 shs
Average Volume868,728 shs
Market Capitalization$1.08 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.71

Competitors

Mesoblast (NASDAQ:MESO) Vs. BEAM, SWTX, RLAY, RVMD, NK, and EDIT

Should you be buying MESO stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Mesoblast, including Beam Therapeutics (BEAM), SpringWorks Therapeutics (SWTX), Relay Therapeutics (RLAY), Revolution Medicines (RVMD), NantKwest (NK), and Editas Medicine (EDIT).

Mesoblast (NASDAQ:MESO) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Valuation and Earnings

This table compares Mesoblast and Beam Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$32.16 million33.51$-77,940,000.00($0.74)-12.39
Beam Therapeutics$20,000.00210,416.58$-78,330,000.00($14.05)-5.17

Mesoblast has higher revenue and earnings than Beam Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mesoblast and Beam Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mesoblast-591.00%-18.69%-13.85%
Beam Therapeutics-529,075.00%-103.41%-48.05%

Insider & Institutional Ownership

2.8% of Mesoblast shares are held by institutional investors. Comparatively, 49.8% of Beam Therapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 0.7% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Mesoblast and Beam Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mesoblast13202.17
Beam Therapeutics03302.50

Mesoblast currently has a consensus price target of $14.55, indicating a potential upside of 58.67%. Beam Therapeutics has a consensus price target of $96.00, indicating a potential upside of 32.23%. Given Mesoblast's higher probable upside, analysts clearly believe Mesoblast is more favorable than Beam Therapeutics.

Summary

Mesoblast beats Beam Therapeutics on 8 of the 13 factors compared between the two stocks.

Mesoblast (NASDAQ:MESO) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Valuation and Earnings

This table compares Mesoblast and SpringWorks Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$32.16 million33.51$-77,940,000.00($0.74)-12.39
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-20.96

SpringWorks Therapeutics has lower revenue, but higher earnings than Mesoblast. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Mesoblast, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Mesoblast has a beta of 3.71, suggesting that its share price is 271% more volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.

Profitability

This table compares Mesoblast and SpringWorks Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mesoblast-591.00%-18.69%-13.85%
SpringWorks TherapeuticsN/A-24.48%-23.58%

Insider & Institutional Ownership

2.8% of Mesoblast shares are held by institutional investors. Comparatively, 76.3% of SpringWorks Therapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 51.2% of SpringWorks Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Mesoblast and SpringWorks Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mesoblast13202.17
SpringWorks Therapeutics00303.00

Mesoblast currently has a consensus price target of $14.55, indicating a potential upside of 58.67%. SpringWorks Therapeutics has a consensus price target of $91.00, indicating a potential upside of 22.31%. Given Mesoblast's higher probable upside, analysts clearly believe Mesoblast is more favorable than SpringWorks Therapeutics.

Summary

Mesoblast beats SpringWorks Therapeutics on 7 of the 13 factors compared between the two stocks.

Mesoblast (NASDAQ:MESO) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Valuation and Earnings

This table compares Mesoblast and Relay Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$32.16 million33.51$-77,940,000.00($0.74)-12.39
Relay TherapeuticsN/AN/AN/AN/AN/A

Relay Therapeutics has lower revenue, but higher earnings than Mesoblast.

Profitability

This table compares Mesoblast and Relay Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mesoblast-591.00%-18.69%-13.85%
Relay TherapeuticsN/AN/AN/A

Insider & Institutional Ownership

2.8% of Mesoblast shares are held by institutional investors. Comparatively, 98.4% of Relay Therapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Mesoblast and Relay Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mesoblast13202.17
Relay Therapeutics01502.83

Mesoblast currently has a consensus price target of $14.55, indicating a potential upside of 58.67%. Relay Therapeutics has a consensus price target of $57.40, indicating a potential upside of 53.52%. Given Mesoblast's higher probable upside, analysts clearly believe Mesoblast is more favorable than Relay Therapeutics.

Summary

Relay Therapeutics beats Mesoblast on 6 of the 9 factors compared between the two stocks.

Mesoblast (NASDAQ:MESO) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Insider & Institutional Ownership

2.8% of Mesoblast shares are held by institutional investors. Comparatively, 85.8% of Revolution Medicines shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Mesoblast and Revolution Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mesoblast-591.00%-18.69%-13.85%
Revolution Medicines-191.17%-32.25%-20.55%

Valuation and Earnings

This table compares Mesoblast and Revolution Medicines' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$32.16 million33.51$-77,940,000.00($0.74)-12.39
Revolution Medicines$50.04 million60.36$-47,660,000.00N/AN/A

Revolution Medicines has higher revenue and earnings than Mesoblast.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Mesoblast and Revolution Medicines, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mesoblast13202.17
Revolution Medicines01402.80

Mesoblast currently has a consensus price target of $14.55, indicating a potential upside of 58.67%. Revolution Medicines has a consensus price target of $50.75, indicating a potential upside of 11.54%. Given Mesoblast's higher probable upside, analysts clearly believe Mesoblast is more favorable than Revolution Medicines.

Summary

Revolution Medicines beats Mesoblast on 7 of the 11 factors compared between the two stocks.

NantKwest (NASDAQ:NK) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Institutional & Insider Ownership

9.4% of NantKwest shares are held by institutional investors. Comparatively, 2.8% of Mesoblast shares are held by institutional investors. 71.7% of NantKwest shares are held by company insiders. Comparatively, 18.8% of Mesoblast shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares NantKwest and Mesoblast's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NantKwest-76,658.58%-56.06%-46.93%
Mesoblast-591.00%-18.69%-13.85%

Earnings and Valuation

This table compares NantKwest and Mesoblast's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NantKwest$40,000.0073,027.99$-65,790,000.00($0.70)-38.29
Mesoblast$32.16 million33.51$-77,940,000.00($0.74)-12.39

NantKwest has higher earnings, but lower revenue than Mesoblast. NantKwest is trading at a lower price-to-earnings ratio than Mesoblast, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

NantKwest has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Comparatively, Mesoblast has a beta of 3.71, indicating that its stock price is 271% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for NantKwest and Mesoblast, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NantKwest00103.00
Mesoblast13202.17

NantKwest currently has a consensus target price of $18.00, indicating a potential downside of 32.84%. Mesoblast has a consensus target price of $14.55, indicating a potential upside of 58.67%. Given Mesoblast's higher possible upside, analysts plainly believe Mesoblast is more favorable than NantKwest.

Summary

Mesoblast beats NantKwest on 8 of the 14 factors compared between the two stocks.

Editas Medicine (NASDAQ:EDIT) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Institutional & Insider Ownership

87.5% of Editas Medicine shares are held by institutional investors. Comparatively, 2.8% of Mesoblast shares are held by institutional investors. 0.9% of Editas Medicine shares are held by company insiders. Comparatively, 18.8% of Mesoblast shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Editas Medicine and Mesoblast's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Editas Medicine-99.62%-26.74%-16.38%
Mesoblast-591.00%-18.69%-13.85%

Earnings and Valuation

This table compares Editas Medicine and Mesoblast's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Editas Medicine$20.53 million136.60$-133,750,000.00($2.68)-15.53
Mesoblast$32.16 million33.51$-77,940,000.00($0.74)-12.39

Mesoblast has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Mesoblast, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Editas Medicine has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Comparatively, Mesoblast has a beta of 3.71, indicating that its stock price is 271% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Editas Medicine and Mesoblast, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Editas Medicine34302.00
Mesoblast13202.17

Editas Medicine currently has a consensus target price of $49.2222, indicating a potential upside of 18.24%. Mesoblast has a consensus target price of $14.55, indicating a potential upside of 58.67%. Given Mesoblast's stronger consensus rating and higher possible upside, analysts plainly believe Mesoblast is more favorable than Editas Medicine.

Summary

Mesoblast beats Editas Medicine on 10 of the 14 factors compared between the two stocks.


Mesoblast Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$72.60-1.2%$4.21 billion$20,000.00-5.17Gap Down
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.6$74.40-6.9%$3.64 billionN/A-42.76Analyst Report
High Trading Volume
Gap Up
RLAY
Relay Therapeutics
1.8$37.39-7.0%$3.36 billionN/A0.00Gap Down
Revolution Medicines logo
RVMD
Revolution Medicines
1.5$45.50-6.7%$3.02 billion$50.04 million0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
NantKwest logo
NK
NantKwest
1.1$26.80-3.9%$2.92 billion$40,000.00-37.75Decrease in Short Interest
Gap Down
Editas Medicine logo
EDIT
Editas Medicine
1.4$41.63-3.1%$2.80 billion$20.53 million-23.93Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$63.37-3.7%$2.79 billion$125.57 million-37.06Earnings Announcement
Analyst Report
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.88-0.8%$2.49 billion$31.43 million-6.08Analyst Revision
News Coverage
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$48.18-4.8%$2.14 billionN/A0.00Upcoming Earnings
News Coverage
Gap Up
AlloVir logo
ALVR
AlloVir
1.4$30.52-13.1%$1.99 billionN/A0.00Insider Selling
High Trading Volume
Gap Down
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$11.15-2.1%$1.98 billion$48.83 million-14.67
Vericel logo
VCEL
Vericel
1.5$42.51-4.9%$1.95 billion$117.85 million-4,251,000.00Analyst Report
Analyst Revision
Gap Up
bluebird bio logo
BLUE
bluebird bio
1.8$28.68-2.6%$1.93 billion$44.67 million-2.61Analyst Report
Gap Up
Scholar Rock logo
SRRK
Scholar Rock
1.3$53.53-5.5%$1.80 billion$20.49 million-22.21Upcoming Earnings
News Coverage
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$41.63-6.1%$1.79 billionN/A0.00Upcoming Earnings
News Coverage
Gap Up
Translate Bio logo
TBIO
Translate Bio
1.4$22.23-4.2%$1.65 billion$7.80 million-20.78Upcoming Earnings
Analyst Revision
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.74-2.6%$1.64 billionN/A-5.91Analyst Report
Unusual Options Activity
Analyst Revision
Gap Down
Replimune Group logo
REPL
Replimune Group
1.5$35.31-8.5%$1.64 billionN/A-19.95High Trading Volume
News Coverage
Gap Up
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.36-1.1%$1.63 billion$102.43 million-18.93Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$72.74-1.5%$1.61 billionN/A-49.15Earnings Announcement
Analyst Upgrade
Analyst Revision
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.93-1.8%$1.49 billion$35.23 million-16.10Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.87-1.3%$1.39 billion$100.56 million0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Alector logo
ALEC
Alector
1.3$17.07-4.8%$1.36 billion$21.22 million-7.65Analyst Upgrade
News Coverage
Gap Up
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$16.07-1.1%$1.34 billionN/A-3.48Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Immunovant logo
IMVT
Immunovant
1.8$13.51-3.2%$1.32 billionN/A-10.47Increase in Short Interest
PCVX
Vaxcyte
1.8$23.76-0.6%$1.21 billionN/A0.00Upcoming Earnings
Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.83-3.7%$1.15 billion$356.07 million7.76Analyst Report
Gap Up
Cortexyme logo
CRTX
Cortexyme
1.3$37.99-4.3%$1.12 billionN/A-15.83Earnings Announcement
Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$29.36-20.3%$1.11 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$11.12-1.4%$1.09 billion$250,000.00-8.76Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.3$12.56-17.2%$1.02 billionN/A-5.87News Coverage
Gap Up
Inhibrx logo
INBX
Inhibrx
1.7$26.39-0.6%$995.22 millionN/A0.00Upcoming Earnings
Gap Down
Passage Bio logo
PASG
Passage Bio
1.9$19.83-2.0%$910.53 millionN/A0.00Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Gap Up
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.10-5.5%$906.51 millionN/A-4.15News Coverage
Gap Up
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.75-2.7%$879.69 million$69.89 million-4.47Gap Down
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$22.41-3.9%$854.22 millionN/A0.00Gap Up
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.80-3.0%$828.87 millionN/A-10.25
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$21.11-3.9%$814.93 million$42.74 million-234.56Gap Up
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.13-2.3%$794.02 million$1.12 million-5.18Analyst Upgrade
Gap Up
Cellectis logo
CLLS
Cellectis
1.3$18.19-6.2%$772.82 million$22.99 million-9.68Earnings Announcement
News Coverage
Gap Down
Vaxart logo
VXRT
Vaxart
1.3$6.02-1.7%$708.96 million$9.86 million-10.20Analyst Report
Analyst Revision
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.76-1.5%$657.51 million$2.51 million-4.10Earnings Announcement
Analyst Report
Increase in Short Interest
Analyst Revision
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$31.54-2.9%$640.89 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.18-0.6%$623.06 millionN/A0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.20-1.3%$608.48 million$150.05 million-2.94
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.50-4.2%$603.52 million$22.24 million-5.72Upcoming Earnings
Analyst Report
Gap Up
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.21-3.6%$572.36 million$14.75 million-2.24Upcoming Earnings
Gap Up
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$12.60-9.1%$571.96 million$147.87 million-4.19Analyst Upgrade
News Coverage
Gap Up
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$9.40-6.1%$568.22 millionN/A-4.56Upcoming Earnings
News Coverage
Gap Up
Compugen logo
CGEN
Compugen
1.4$8.30-1.6%$567.54 million$17.80 million-22.42Analyst Downgrade
High Trading Volume
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.